Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

CellRapeutics™ Anti-Cryptococcus neoformans CAR Cell Therapy Development Service

Online Inquiry

Background Services Required Starting Materials Workflow HCMV Antigen Types Advantages FAQs Contact Us

To address persistent fungal infections, limited treatment options, and the challenge of drug resistance in immunocompromised patients, Creative Biolabs delivers a cost-effective CellRapeutics™ anti-Cryptococcus neoformans CAR Cell therapy development service that helps you develop highly effective and specific CAR cell therapies to combat this critical pathogen through advanced CAR engineering, robust cell manufacturing, and comprehensive preclinical validation.

The Potential of CAR-T in the Treatment of Cryptococcus NeoformansInfection

Cryptococcus neoformans(C. neoformans) remains a significant global health threat, particularly for immunocompromised individuals, causing severe meningoencephalitis and pulmonary infections. Current antifungal treatments often face limitations such as drug resistance, toxicity, and inadequate efficacy in severe cases. Gene therapy, specifically Chimeric Antigen Receptor (CAR) T-cell therapy, has revolutionized cancer treatment and is now emerging as a promising strategy for infectious diseases. Research highlights the potential of CAR T cells to target fungal pathogens like C. neoformans by recognizing specific fungal antigens, offering a novel, highly targeted, and potent fungicidal approach to overcome the shortcomings of conventional therapies.

Fig.1 Cryptococcal virulence factors are key mechanisms that manipulate the host's immune response.¹

CellRapeutics™ Anti-Cryptococcus neoformans CAR Cell Therapy Development Service at Creative Biolabs

Creative Biolabs' CellRapeutics™ anti-C. neoformans CAR cell therapy development service delivers a comprehensive, end-to-end solution for the development of targeted cellular immunotherapies engineered to combat the challenging fungal pathogen, C. neoformans. This service encompasses expert custom CAR construct design, state-of-the-art high-quality CAR cell production, and robust in vitro and in vivo efficacy testing. Through these integrated capabilities, clients receive a meticulously developed, potent, and highly specific therapeutic candidate ready for further preclinical and clinical advancement.

Required Starting Materials

Target Antigen Information: Details on specific Cryptococcus neoformans antigens or virulence factors that could serve as targets for CAR recognition.
Immune Cell Source Specifications: If applicable, information regarding the desired source of immune cells (e.g., human peripheral blood mononuclear cells, specific T cell subsets) for CAR engineering.
Project Goals and Specifications: Clear objectives for the CAR cell therapy, including desired specificity, potency, and preclinical validation requirements.

One-stop Customized Workflow

Step 1

Target Antigen Identification & CAR Construct Design

Our experts assist in identifying optimal C. neoformans-specific antigens that are accessible and critical for fungal survival or virulence. Based on this, we design CAR constructs, selecting appropriate single-chain variable fragments (scFvs), hinge regions, transmembrane domains, and intracellular signaling domains (e.g., CD3ζ, 4-1BB, CD28) to ensure optimal specificity and robust T-cell activation.

Step 2

Vector Construction & Production

The designed CAR construct is cloned into high-quality viral vectors, typically lentiviral or retroviral, known for their efficient gene transfer capabilities. We then proceed with the large-scale production of these recombinant viral vectors, ensuring high titers and purity suitable for cell transduction.

Step 3

CAR Cell Transduction & Expansion

Immune cells (e.g., T cells, NK cells) are isolated, activated, and then transduced with the CAR-encoding viral vectors. Following successful transduction, the CAR-expressing cells are expanded ex vivo under optimized conditions to achieve the desired cell numbers while maintaining viability, phenotype, and functionality. Rigorous quality control checks are performed throughout the expansion phase.

Step 4

In Vitro Functional Validation

Primary human T cells are isolated, activated, transduced with the CAR-expressing viral vectors, and expanded to therapeutic numbers under optimized conditions, ensuring high viability and transduction efficiency

Step 5

In Vitro Efficacy & Safety Evaluation

The engineered CAR cells undergo comprehensive in vitro functional assays. This includes assessing their specificity against C. neoformans and non-target cells, evaluating their fungicidal activity (e.g., fungal killing assays, growth inhibition assays), cytokine secretion profiles upon antigen encounter, and proliferation capabilities.

Step 6

In Vivo Preclinical Efficacy Assessment (Optional)

For advanced projects, we offer in vivo preclinical efficacy assessment using relevant animal models of cryptococcosis. This involves administering the CAR cells to infected models and monitoring fungal burden reduction in various organs, survival rates, and potential off-target toxicities or adverse events.

Engineerable C. Neoformans Antigen Targets

The success of CAR cell therapy hinges on the identification of specific and accessible antigen targets on the surface of C. neoformans. Ideal targets are those that are consistently expressed by the pathogen, critical for its survival or virulence, and minimally expressed on host cells to avoid off-target toxicity. Key potential antigen targets for engineering anti-C. neoformans CAR cells include:

Glucuronoxylomannan (GXM): The primary and most abundant component of the C. neoformans polysaccharide capsule. GXM is highly immunogenic and shed during infection, making it an attractive and accessible target for CAR recognition.
Glucuronoxylomannogalactan (GXMGal): Another major capsular polysaccharide, less abundant than GXM, but presenting unique targetable epitopes.
Melanin: Produced by C. neoformans and integrated into its cell wall, this virulence factor protects the fungus. Specific melanin-associated antigens could serve as targets.
Chitin and Chitosan: Essential structural components of the fungal cell wall. Though broadly conserved, specific modifications or exposed epitopes unique to C. neoformans can be exploited.
Mannoproteins: Various glycosylated proteins on the fungal cell wall. Some are unique to C. neoformans and play roles in adhesion and immune evasion, making them potential targets.
Phospholipomannan (PLM): A glycoconjugate found in the cell wall and capsule, PLM modulates immune responses and presents unique antigenic determinants.

Attractive Advantages

Precisely targets fungal pathogens, minimizing off-target effects.
Delivers strong and direct killing of Cryptococcus neoformans.
Offers durable therapeutic effects against recurrent infections.
Less systemic toxicity compared to conventional antifungals.
Provides an effective solution for drug-resistant fungal strains.
A comprehensive approach for challenging Cryptococcus neoformans infections.

FAQs

Q1: How long does the development process typically take, and what are the key milestones?

A1: The project timeline can vary based on complexity, but generally ranges from 12 to 24 weeks, encompassing stages from CAR construct design and cell manufacturing to comprehensive in vitro and in vivo validation. We provide regular updates and detailed reports at each milestone. Please reach out for a customized project proposal and timeline.

Q2: Can Creative Biolabs assist with preclinical validation of the developed CAR cell therapies?

A2: Absolutely. Our service includes robust in vitro functional assays and in vivo efficacy assessments in relevant animal models of cryptococcosis to thoroughly evaluate the therapeutic potential and safety profile of your CAR cell candidate. We welcome you to discuss your specific preclinical needs with our scientific team.

Related Services

To further support your research and development goals, Creative Biolabs offers a range of complementary services that can synergize with your anti-C. neoformans CAR cell therapy project:

Why Choose Us

At Creative Biolabs, we are dedicated to advancing your anti-C. neoformansCAR cell therapy project with unparalleled expertise and cutting-edge facilities. Our dedicated scientific team brings deep knowledge in immunology, mycology, and gene therapy, ensuring a comprehensive and robust approach from concept to preclinical validation. We uphold stringent quality control throughout our pipeline, guaranteeing high-quality, functional CAR cell products. Please feel free to get in touch with us to discover how our service accelerates your meaningful projects.

Reference

Chen, Yanli et al. "Cryptococcus neoformans Infection in the Central Nervous System: The Battle between Host and Pathogen." Journal of fungi (Basel, Switzerland) vol. 8,10 1069. 12 Oct. 2022, doi:10.3390/jof8101069. Distributed under Open Access License CC BY 4.0, without modification.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.